HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

apitegromab

monoclonal antibody that binds to human promyostatin and latent myostatin

Also Known As:

SRK-015

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cote, Shaun M: 2 articles (07/2021 - 01/2021)
2.	Kalra, Ashish: 2 articles (07/2021 - 01/2021)
3.	Jackson, Justin: 1 article (07/2021)
4.	Lansita, Janice: 1 article (07/2021)
5.	Meshulam, Deborah: 1 article (07/2021)
6.	Pal, Ajai: 1 article (07/2021)
7.	Welsh, Brian T: 1 article (07/2021)
8.	Barrett, Doreen: 1 article (01/2021)
9.	Bilic, Sanela: 1 article (01/2021)
10.	Chyung, Yung: 1 article (01/2021)

Related Diseases

1.	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 07/01/2021 - "These data support the conduct of ongoing clinical studies of apitegromab in adult and pediatric patients with spinal muscular atrophy (SMA)." 01/01/2021 - "These results support continued investigation of apitegromab for the treatment of patients with milder forms (type 2 and 3) of spinal muscular atrophy." 01/01/2021 - "A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy." 01/01/2021 - "Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody under development to improve motor function in patients with spinal muscular atrophy, a rare neuromuscular disease. "
2.	Neuromuscular Diseases (Neuromuscular Disease) 01/01/2021 - "Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody under development to improve motor function in patients with spinal muscular atrophy, a rare neuromuscular disease. "

Related Drugs and Biologics

1.	Myostatin
2.	Monoclonal Antibodies